These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 28039467)

  • 1. Targeting cancer stem cell propagation with palbociclib, a CDK4/6 inhibitor: Telomerase drives tumor cell heterogeneity.
    Bonuccelli G; Peiris-Pages M; Ozsvari B; Martinez-Outschoorn UE; Sotgia F; Lisanti MP
    Oncotarget; 2017 Feb; 8(6):9868-9884. PubMed ID: 28039467
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature.
    Knudsen ES; Hutcheson J; Vail P; Witkiewicz AK
    Oncotarget; 2017 Jul; 8(27):43678-43691. PubMed ID: 28620137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress of CDK4/6 Inhibitor Palbociclib in the Treatment of Cancer.
    Chen F; Liu C; Zhang J; Xu W; Zhang Y
    Anticancer Agents Med Chem; 2018; 18(9):1241-1251. PubMed ID: 28403773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemoproteomics Reveals Novel Protein and Lipid Kinase Targets of Clinical CDK4/6 Inhibitors in Lung Cancer.
    Sumi NJ; Kuenzi BM; Knezevic CE; Remsing Rix LL; Rix U
    ACS Chem Biol; 2015 Dec; 10(12):2680-6. PubMed ID: 26390342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Palbociclib has antitumour effects on Pten-deficient endometrial neoplasias.
    Dosil MA; Mirantes C; Eritja N; Felip I; Navaridas R; Gatius S; Santacana M; Colàs E; Moiola C; Schoenenberger JA; Encinas M; Garí E; Matias-Guiu X; Dolcet X
    J Pathol; 2017 Jun; 242(2):152-164. PubMed ID: 28349562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Palbociclib, a selective CDK4/6 inhibitor, enhances the effect of selumetinib in RAS-driven non-small cell lung cancer.
    Zhou J; Zhang S; Chen X; Zheng X; Yao Y; Lu G; Zhou J
    Cancer Lett; 2017 Nov; 408():130-137. PubMed ID: 28866094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
    Bisi JE; Sorrentino JA; Jordan JL; Darr DD; Roberts PJ; Tavares FX; Strum JC
    Oncotarget; 2017 Jun; 8(26):42343-42358. PubMed ID: 28418845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-Cell Dynamics Determines Response to CDK4/6 Inhibition in Triple-Negative Breast Cancer.
    Asghar US; Barr AR; Cutts R; Beaney M; Babina I; Sampath D; Giltnane J; Lacap JA; Crocker L; Young A; Pearson A; Herrera-Abreu MT; Bakal C; Turner NC
    Clin Cancer Res; 2017 Sep; 23(18):5561-5572. PubMed ID: 28606920
    [No Abstract]   [Full Text] [Related]  

  • 9. Targeting flavin-containing enzymes eliminates cancer stem cells (CSCs), by inhibiting mitochondrial respiration: Vitamin B2 (Riboflavin) in cancer therapy.
    Ozsvari B; Bonuccelli G; Sanchez-Alvarez R; Foster R; Sotgia F; Lisanti MP
    Aging (Albany NY); 2017 Dec; 9(12):2610-2628. PubMed ID: 29253841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual cyclin-dependent kinase 4/6 inhibition by PD-0332991 induces apoptosis and senescence in oesophageal squamous cell carcinoma cells.
    Chen L; Pan J
    Br J Pharmacol; 2017 Aug; 174(15):2427-2443. PubMed ID: 28444744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation between telomerase and mTOR pathway in cancer stem cells.
    Dogan F; Biray Avci C
    Gene; 2018 Jan; 641():235-239. PubMed ID: 29074462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of CDK4 sensitizes multidrug resistant ovarian cancer cells to paclitaxel by increasing apoptosiss.
    Gao Y; Shen J; Choy E; Mankin H; Hornicek F; Duan Z
    Cell Oncol (Dordr); 2017 Jun; 40(3):209-218. PubMed ID: 28243976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined Inhibition of CDK4/6 and PI3K/AKT/mTOR Pathways Induces a Synergistic Anti-Tumor Effect in Malignant Pleural Mesothelioma Cells.
    Bonelli MA; Digiacomo G; Fumarola C; Alfieri R; Quaini F; Falco A; Madeddu D; La Monica S; Cretella D; Ravelli A; Ulivi P; Tebaldi M; Calistri D; Delmonte A; Ampollini L; Carbognani P; Tiseo M; Cavazzoni A; Petronini PG
    Neoplasia; 2017 Aug; 19(8):637-648. PubMed ID: 28704762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stromal Senescence By Prolonged CDK4/6 Inhibition Potentiates Tumor Growth.
    Guan X; LaPak KM; Hennessey RC; Yu CY; Shakya R; Zhang J; Burd CE
    Mol Cancer Res; 2017 Mar; 15(3):237-249. PubMed ID: 28039358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.
    Bagegni N; Thomas S; Liu N; Luo J; Hoog J; Northfelt DW; Goetz MP; Forero A; Bergqvist M; Karen J; Neumüller M; Suh EM; Guo Z; Vij K; Sanati S; Ellis M; Ma CX
    Breast Cancer Res; 2017 Nov; 19(1):123. PubMed ID: 29162134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Palbociclib induces activation of AMPK and inhibits hepatocellular carcinoma in a CDK4/6-independent manner.
    Hsieh FS; Chen YL; Hung MH; Chu PY; Tsai MH; Chen LJ; Hsiao YJ; Shih CT; Chang MJ; Chao TI; Shiau CW; Chen KF
    Mol Oncol; 2017 Aug; 11(8):1035-1049. PubMed ID: 28453226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer stem cell-like characteristics and telomerase activity of the nasopharyngeal carcinoma radioresistant cell line CNE-2R.
    Chen KH; Guo Y; Li L; Qu S; Zhao W; Lu QT; Mo QY; Yu BB; Zhou L; Lin GX; Sun YC; Zhu XD
    Cancer Med; 2018 Sep; 7(9):4755-4764. PubMed ID: 30105829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thermal proteome profiling of breast cancer cells reveals proteasomal activation by CDK4/6 inhibitor palbociclib.
    Miettinen TP; Peltier J; Härtlova A; Gierliński M; Jansen VM; Trost M; Björklund M
    EMBO J; 2018 May; 37(10):. PubMed ID: 29669860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclin E overexpression confers resistance to the CDK4/6 specific inhibitor palbociclib in gastric cancer cells.
    Min A; Kim JE; Kim YJ; Lim JM; Kim S; Kim JW; Lee KH; Kim TY; Oh DY; Bang YJ; Im SA
    Cancer Lett; 2018 Aug; 430():123-132. PubMed ID: 29729292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The anti-tumor efficacy of CDK4/6 inhibition is enhanced by the combination with PI3K/AKT/mTOR inhibitors through impairment of glucose metabolism in TNBC cells.
    Cretella D; Ravelli A; Fumarola C; La Monica S; Digiacomo G; Cavazzoni A; Alfieri R; Biondi A; Generali D; Bonelli M; Petronini PG
    J Exp Clin Cancer Res; 2018 Mar; 37(1):72. PubMed ID: 29587820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.